Published on: August 17, 2020
According to a new study, death rates from non-small cell lung cancer have fallen sharply in recent years, mostly due to advances in treatment.
Published on: June 18, 2020
The US Food and Drug Administration (FDA) has expanded the approval of the immunotherapy drug pembrolizumab (Keytruda) to include any cancer with a high tumor mutational burden (TMB-H).
Published on: December 20, 2019
The US Food and Drug Administration (FDA) has approved a new type of drug for certain people with bladder cancer.
Published on: December 6, 2019
In 2019, the FDA approved several new drug treatments for different cancer types. Here are the stories that made headlines on cancer.org this year.
Published on: March 19, 2019
The US Food and Drug Administration (FDA) has approved the immunotherapy drug Tecentriq (atezolizumab) for the treatment of small cell lung cancer (SCLC).
Published on: March 11, 2019
The US Food and Drug Administration today approved the first immunotherapy treatment for breast cancer. It approved a combination of Tecentriq (atezolizumab) and Abraxane (nab-paclitaxel) for people with advanced triple negative breast cancer.
Published on: December 28, 2018
In 2018, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
Published on: October 30, 2018
A study by an international group of researchers has found for the first time that a combination of immunotherapy and chemotherapy can extend lives of women with triple-negative breast cancer.